Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Lumen Technologies Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Lumen Technologies Inc trades at $4.48 (market cap $5.14B). The key difference: Lumen Technologies Inc is the larger of the two by market cap, and Lumen Technologies Inc is more actively traded (15,538,010 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Lumen Technologies Inc for 40 Days on average.
| DYN | LUMN | |
|---|---|---|
Market Cap | $2.86B | $5.14B |
Volume | 3,341,579 | 15,538,010 |
Sector | Health | Media |
52-Week High | $26.78 | $11.83 |
52-Week Low | $14.60 | $4.55 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $2.18B | $16.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
LUMN trades at $4.99, down 1.19% on the day, with a bearish technical outlook and mixed earnings history. Revenue has declined from $17.5B in 2022 to $12.4B in 2025, with a net loss of $1.74B last year. The company is pivoting to AI and digital networking services, recently announcing a Nasdaq listing and launching Intelligent Internet to capture enterprise demand.
The stock presents a high-risk turnaround opportunity, with deep value indicated by a low P/S of 0.42 but significant challenges including high debt, negative margins, and analyst skepticism. Strategic growth in AI services offers potential upside, but legacy declines and financial instability pose substantial risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
